|Articles|April 27, 2023
Talking Automation in Fill/Finish and Cell & Gene Therapies with James Rorke (INTERPHEX 2023)
James Rorke, vice-president, operations, Steriline North America, discusses the benefits of automation in fill/finish operations.
Advertisement
James Rorke, vice-president, operations, Steriline North America, discusses the advantages of automation in fill/finish, particulary for low volume, high quaility products such as cell and gene therapies, for which minimizing product loss is crucial.
For more INTERPHEX 2023 video content, check
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Developing Next-Gen Cell Lines Using Targeted Integration
2
FAQ: What You Need to Know about the Current Antibody Pipeline
3
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
4
FAQ: What Precision Analytics Have Done to Advance Next-Gen Biologics
5